Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Green Cross Seeks To Unveil Injectable Flu Antiviral Peramivir Even Before KFDA Approval

This article was originally published in PharmAsia News

Executive Summary

SEOUL - With or without an approval from Korea FDA, South Korea's vaccine producer Green Cross is gearing up to launch its version of injectable antiviral peramivir, which was developed by BioCryst Pharmaceuticals for treatment of influenza

You may also be interested in...



Green Cross Obtains South Korean Approval For Peramivir During Drive To Secure More Anti-Influenza Medicines Beyond Roche and GSK Products

SEOUL - South Korea's Green Cross has obtained approval from South Korea's FDA to sell the injectable antiviral drug Rapiacta (peramivir), developed by BioCryst Pharmaceuticals in the U.S., during a government drive to make more flu-fighting medicines available beyond Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)

Green Cross Obtains South Korean Approval For Peramivir During Drive To Secure More Anti-Influenza Medicines Beyond Roche and GSK Products

SEOUL - South Korea's Green Cross has obtained approval from South Korea's FDA to sell the injectable antiviral drug Rapiacta (peramivir), developed by BioCryst Pharmaceuticals in the U.S., during a government drive to make more flu-fighting medicines available beyond Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)

Green Cross Obtains South Korean Approval For BioCryst Influenza Therapy Peramivir

The deal is part of a drive to secure anti-influenza options beyond Roche and GSK products in preparation for the next round of global influenza.

Related Content

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel